Holen Sie sich die Stockscreener-App
2.17
0.93%
0.02
Handel nachbörslich:
2.16
-0.010
-0.46%
Schlusskurs vom Vortag:
$2.15
Offen:
$2.1425
24-Stunden-Volumen:
18,552
Relative Volume:
0.03
Marktkapitalisierung:
$2.99M
Einnahmen:
$2.45M
Nettoeinkommen (Verlust:
$-5.47M
KGV:
-0.0367
EPS:
-59.1634
Netto-Cashflow:
$-6.05M
1W Leistung:
+3.83%
1M Leistung:
-10.33%
6M Leistung:
+6.37%
1J Leistung:
-98.31%
1-Tages-Spanne:
$2.12
$2.20
1-Wochen-Bereich:
$2.05
$2.2497
52-Wochen-Spanne:
$0.6273
$134.28
Pmgc Holdings Inc Stock (ELAB) Company Profile
Firmenname
Pmgc Holdings Inc
Sektor
Branche
Telefon
888-445-4886
Adresse
120 NEWPORT CENTER DRIVE, NEWPORT BEACH
Vergleichen Sie ELAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAB
Pmgc Holdings Inc
|
2.17 | 2.92M | 2.45M | -5.47M | -6.05M | -59.16 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Pmgc Holdings Inc Aktie (ELAB) Neueste Nachrichten
Elevai Labs stock plunges to 52-week low of $2.09 amid steep decline By Investing.com - Investing.com South Africa
Elevai Labs stock plunges to 52-week low of $2.09 amid steep decline - Investing.com Australia
Northstrive Biosciences completes phase I research on muscle-wasting treatment - Investing.com
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia - GlobeNewswire
Northstrive Biosciences Amends License Agreement with MOA Life - TipRanks
PMGC Holdings Inc. Files Quarterly Report for Q1 2025, Highlights Strategic Growth Initiatives - Nasdaq
PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q - The Manila Times
PMGC Holdings Expands into Hot GLP-1 Market While Pursuing Tech Acquisition: Q1 2025 Details Released - Stock Titan
PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market - ADVFN
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. - GlobeNewswire
PMGC Capital Takes 5.09% Stake in Alaunos Therapeutics, Eyes Strategic Changes Including Fintech Expansion - Stock Titan
PMGC Holdings inks employee secondment deal with Northstrive By Investing.com - Investing.com Nigeria
PMGC Holdings inks employee secondment deal with Northstrive - Investing.com
Northstrive Biosciences Signs Binding Term Sheet with - GlobeNewswire
Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22 - Stock Titan
PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - ADVFN
PMGC Holdings Inc: Navigating Market Fluctuations with a 2.72M Market Cap - investchronicle.com
ELAB’s price-to-free cash flow ratio: How it affects investment decisions - uspostnews.com
PMGC Holdings (ELAB) Continues Uptrend During Pre-Hours On Positive Sentiment - Stocks Telegraph
ELAB Stock Price and Chart — NASDAQ:ELAB - TradingView
RESENDNorthstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health - GlobeNewswire
Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health - The Manila Times
Northstrive Biosciences Strengthens IP Portfolio with New - GlobeNewswire
Northstrive Expands Patent Portfolio: New GLP-1 Combo Treatment Could Prevent Muscle Loss in Obesity - Stock Titan
Northstrive Biosciences files patents for obesity treatments By Investing.com - Investing.com India
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial - The Manila Times
Northstrive Biosciences Co-Founder Featured on Bear Bull - GlobeNewswire
Elevai Labs stock plunges to 52-week low of $2.22 amid steep decline - Investing.com India
Ratios Reveal: Breaking Down PMGC Holdings Inc (ELAB)’s Financial Health - DWinneX
ELAB’s Stock Journey: What Investors Need to Know About PMGC Holdings Inc’s Performance - investchronicle.com
Elevai Labs stock plunges to 52-week low of $2.22 amid steep decline By Investing.com - Investing.com South Africa
What is ELAB’s price-to-sales ratio telling us about the company’s value? - uspostnews.com
Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment - GlobeNewswire
Key deals this week: Vista Energy, PMGC Holdings, Colliers, John Wood and more - Seeking Alpha
PMGC Signs Letter of Intent to Purchase Custom IT Packaging Firm; Shares Fall - marketscreener.com
ELAB stock touches 52-week low at $2.51 amid steep annual decline - Investing.com
PMGC signs letter of intent to acquire U.S.-based custom IT packaging company - TipRanks
Pmgc Holdings Signs Letter Of Intent To Acquire Profitable U.S.-Based Custom It Packaging Company - MarketScreener
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company - GlobeNewswire
Strategic Acquisition: PMGC Eyes IT Packaging Leader Serving Major Data Centers - Stock Titan
PMGC’s Northstrive Biosciences signs partnership with Yuva Biosciences - TipRanks
PMGC Stock Surges After Subsidiary Inks Deal With Yuva Biosciences To Develop AI Led Therapies - Benzinga
ELAB Stock Soars: Buy Now Or Wait? - timothysykes.com
Northstrive Biosciences Signs Partnership with Yuva - GlobeNewswire
Elevai Labs stock plunges to 52-week low of $3.86 amid steep decline - Investing.com Australia
Elevai Labs stock plunges to 52-week low of $3.86 amid steep decline By Investing.com - Investing.com South Africa
PMGC Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - MarketScreener
PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K - The Manila Times
PMGC Holdings Targets Multiple Acquisitions to Accelerate Growth Strategy - Stock Titan
Finanzdaten der Pmgc Holdings Inc-Aktie (ELAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):